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Abstract
Background: Incidental adrenal masses are commonly detected during imaging for other pathologies. 10% of the elderly
population has an ‘adrenal incidentaloma’, up to 20% of these show low-grade autonomous cortisol secretion and 60% of
patients with autonomous cortisol secretion have insulin resistance. Cortisol excess is known to cause insulin resistance, an
independent cardiovascular risk marker, however in patients with adrenal incidentalomas it is unknown whether their
insulin resistance is secondary to the excess cortisol and therefore potentially reversible. In a proof of concept study we
examined the short-term effects of glucocorticoid receptor (GR) antagonism in patients with an adrenal incidentaloma to
determine whether their insulin resistance was reversible.
Methodology/Principal Findings: In a prospective open-label pilot study, six individuals with adrenal incidentalomas and
autonomous cortisol secretion were treated with mifepristone (a GR antagonist) 200 mg twice daily and studied for 4 weeks
on a Clinical Research Facility. Insulin resistance at four weeks was assessed by insulin resistance indices, lnHOMA-IR and
lnMatsuda, and AUC insulin during a 2-hour glucose tolerance test. Biochemical evidence of GR blockade was shown in all
individuals and across the group there was a significant reduction in insulin resistance: lnHOMA-IR (1.0vs0.6; p = 0.03),
lnHOMA-%beta (4.8vs4.3; p = 0.03) and lnMatsuda (1.2vs1.6; p = 0.03). Five out of six individuals showed a reduction in
insulin AUC .7237 pmol/l.min, and in two patients this showed a clinically significant cardiovascular benefit (as defined by
the Helsinki heart study).
Conclusions: Short-term GR antagonism is sufficient to reduce insulin resistance in some individuals with adrenal
incidentalomas and mild cortisol excess. Further assessment is required to assess if the responses may be used to stratify
therapy as adrenal incidentalomas may be a common remediable cause of increased cardiovascular risk.
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Introduction
Adrenal masses incidentally disclosed on computed tomography
(CT) scans, ‘adrenal incidentalomas’ are common. Prevalence
increases during life such that they are found in ten percent of the
population aged 70 years or more [1,2]. Between five to twenty
percent of these are associated with mild cortisol excess without
the classical external features typically associated with Cushing’s
syndrome [3], often termed ‘subclinical Cushing’s syndrome’, or
‘subclinical hypercortisolism’ [4]. One of cortisol’s major functions
is the regulation of glucose metabolism: it promotes gluconeogen-
esis by activation of phosphoenolpyruvate carboxykinase and
glucose-6-phosphatase in the liver [5,6]; inhibits insulin release in
the pancreas [7]; decreases insulin sensitivity in skeletal muscle and
adipose tissue [8]. Consequently, an important complication of
cortisol excess is insulin resistance (IR) [9], a major independent
marker of cardiovascular risk [10], and this is reflected by the fact
that over 60% of individuals with adrenal incidentalomas and low
grade cortisol secretion have IR, impaired glucose tolerance or
diabetes mellitus compared to age, sex and BMI-matched controls
[11]. However, as IR is common in the general population it is
unknown whether the IR in patients with adrenal incidentalomas
is secondary to the low level cortisol secretion or other factors.
The GR antagonist mifepristone (11-[4-(Dimethylamino)phe-
nyl]-17-hydroxy-17-[1-propynyl]-[11ß,17ß]-estra-4,9-dien-3-one)
has been shown to improve glucose tolerance in patients with overt
Cushing’s syndrome [12]. We hypothesized that insulin resistance
in individuals with adrenal incidentalomas and low-grade cortisol
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excess without the classical external features typically associated
with Cushing’s syndrome might also be improved by short-term
GR blockade if in these individuals IR is driven by cortisol excess.
Our findings showed, for the first time, that even short-term GR
blockade in these individuals improved insulin resistance. These
data could inform the design of a much awaited prospective
interventional randomized controlled study aimed to identify
whether such an approach could be used as a prediction tool to
stratify an affected individual to surgery, medical therapy or
observation [13].
Methods
Ethics Statement & Participants
The study protocol was approved by the North Sheffield
Research Ethics committee, and the Medicines and Health
Regulatory Authority, UK and was performed according to the
requirements of the Declaration of Helsinki as revised in 2000.
Written informed consent was obtained from all participants. The
study is reported according to the Transparent Reporting of
Evaluations with Nonrandomized Designs (TREND) [14]. These
are guidelines for the reporting of nonrandomised trials to help
improve the clarity of a report and to encourage more detailed
description of the study design and the findings. The statement
presents a checklist for investigators to follow and which are
mainly directed towards intervention evaluation studies. The
protocol for this trial and supporting TREND checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
This prospective open-label pilot study was performed at the
Clinical Research Facility, Sheffield Teaching Hospitals NHS
Foundation Trust and The University of Sheffield, UK between
January 2010 and March 2010 in six patients. Patients were
identified by continuous sampling from referrals to the Endocrine
Investigation Unit as part of an incidentaloma work-up protocol at
the Royal Hallamshire Hospital, Sheffield. It was planned to
perform the study over 8 weeks, but we analyzed at four weeks,
focusing on IR. Metabolic outcome was achieved and all 6 patients
had IR indices and BP measurements suitable for analysis. After
ingestion of 200 mg of mifepristone, peak concentrations are
reached within 1 to 2 hours, there is an initial redistribution phase
of 6–10 h followed by a plateau for 24 h or more. The terminal
half-life (t1/2) is 30 hours. Dose-dependent antiglucocorticoid
effects last for at least 24 hours after a single dose, hence
significant effects would already be expected by a week [15,16].
Two patients had been withdrawn after four weeks. All subjects
were known to have an adrenal incidentaloma, with benign
characteristics as assessed on CT, lacking external clinical features
classically associated with Cushing’s [4,17,18], but having
evidence of excess cortisol as shown by lack of suppression of
serum cortisol to ,50 nmol/L (1.8 ug/dL) on 1 mg over-night
dexamethasone suppression and 2 mg/day 48 hour low-dose
dexamethasone suppression testing [18]. All were on stable anti-
hypertensive treatment for at least three months and none were on
anti-diabetes medications. Although this was an exploratory
human subject study to assess if insulin resistance could be
reversed and not a formal outcome study per se, it was still
registered at Clinical trials.gov: ID NCT00721201.
Study Design & End-points
The flow chart in Figure 1, as recommended by the TREND
statement, describes the different phases and design of the study.
One patient who was approached and screened did not meet the
entry criteria, whilst one other declined to participate. Study visits
occurred weekly up to week 4 and procedures at each visit are
shown in Figure 2. The baseline glucose tolerance test was
performed on the first day of treatment (treatment start) before the
first dose of mifepristone whilst the baseline 24-hour ambulatory
BP monitoring was performed between the first visit (screening)
and second visit (treatment start). During each visit renal function,
0900 h and 2300 h salivary cortisol (representing free cortisol) and
0900 h plasma ACTH and serum cortisol (total cortisol) levels
were assessed to confirm compliance and efficacy of GR blockade.
All interventions were performed by the clinical research team on
the Facility. Since mifepristone blocks the GR the expectation was
a rise in plasma ACTH and serum and salivary cortisol by
activation of the hypothalamo-pituitary-adrenal (HPA) axis, but
with blockade of GR-mediated activity. Saliva samples were
obtained using the Salivette tubes (cotton swab with citric acid
preparation; Sarstedt, Numbrecht). Subjects were instructed to
refrain from brushing their teeth, smoking, eating or drinking
anything for at least 60 min prior to sampling. To provide a saliva
sample, patients were asked to chew on the cotton swab for 1–
2 min and then place it back in the plastic container. The bone
formation marker serum osteocalcin was measured in a 0900 h
fasting sample, and the second morning urine sample was used to
measure the bone resorption marker urine N-telopeptide crosslinks
of type 1 collagen (NTX). Full clinical assessment including resting
BP, weight and temperature was made at each visit - monitoring
for symptoms and signs for adrenal insufficiency can only be
performed on a clinical, and not biochemical, basis when on
mifepristone. The oral dose of mifepristone was kept the same at
200 mg twice a day at 0900 h and 2100 h, one hour before any
food, throughout the study. Although once daily dosing might
have sufficed, twice daily dosing was chosen in an effort to
maintain as constant a GR blockade effect as possible.
To establish a normal 95% reference range for IR we analyzed
data from the Helsinki Policemen study, a 22 year follow up
investigating what level of IR, as reflected by insulin AUC on an
OGTT, predicted cardiovascular events. By taking the
mean62SD of the values of those followed for 22 years (n = 755)
and in whom no cardiovascular event was observed, we define the
upper end of the 95% reference range of insulin AUC associated
with no cardiovascular risk as 63420 pmol/l.min (2694062SD
pmol/l.min) [10]. In addition we took values ,26940 pmol/l.min
to represent definite normalization of AUC and only a decrease in
insulin AUC greater than 7237 pmol/l.min, during a 2-hour
OGTT, was considered significant as this exceeds biological
variation [19]. The insulin AUC was appropriate for our group as
in patients with fasting insulin levels less than 200 pmol/l the
insulin AUC is reproducible [19]. We chose insulin AUC on
OGTT as our primary estimate of IR as this allowed direct
comparison to the seminal Helsinki heart study data examining the
long term effects of IR on cardiovascular risk. Resting and 24-hour
ambulatory blood pressure as measured using standard British
Hypertension Society approved monitors were other primary end
points.
Secondary end points were the means for fasting glucose, fasting
insulin, the homeostasis model assessment of IR and beta cell
function (HOMA-IR and HOMA-%beta) [20], and the Insulin
Sensitivity Index (ISI) – Matsuda [21], as calculated from an oral
glucose tolerance test. The difference in fasting lipids and bone
turnover markers at study end were also measured.
Assays
Total serum cortisol was measured in a Siemens Advia Centaur
Cortisol assay: analytical range 5.5–2069 nmol/l; inter-assay co-
efficient of variation (CV), 6.2% at 134 nmol/l, 5.5% at
Mifepristone in Adrenal Incidentalomas
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491 nmol/l and 6.0% at 836 nmol/l. Plasma ACTH was
measured in a Siemens Immulite 2000 chemiluminescent assay:
Analytical range 1.1–275 pmol/l; inter-assay CVs 6.4% at
7 pmol/l, 6.5% at 105 pmol/l. Salivary cortisol was measured
by Liquid Chromatography Tandem Mass spectrometry (LC-MS/
MS) as previously described [22]. Glucose was measured using the
Hexokinase method, Beckman Coulter Inc, with CV 2.6% at
3.3 mmol/l and 2.1% at 20.3 mmol/l. Insulin was measured by
Siemens Advia Centaur chemiluminescent immunometric assay
with a CV of 5.3% at 222 pmol/l, 4.9% at 760.5 pmol/l and
5.8% at 1409 pmol/l. The analysis of serum osteocalcin and urine
NTX was performed by Cobas e411 Autoanalyser (Roche
Diagnostics) and the Ortho Clinical Vitros device respectively,
with interassay CV’s of 4.5% and 6.6% respectively. Urine NTX
was expressed as a ratio to urinary creatinine. Standard
biochemistry and hematological methods were used for renal,
liver and thyroid function, lipid profiles and the full blood count.
Statistical Analysis
Statistical analyses were performed using SPSS version 16
(SPSS, Chicago, IL, USA) and Microsoft Office Excel 2010. Rates
were calculated for categorical data, and means and 95%
confidence intervals for continuous data. We used non-parametric
Wilcoxon’s signed rank test for repeated measures to analyze the
effect of up to four weeks of mifepristone treatment on variables of
glucose, insulin and insulin sensitivity, resting and 24 hour BP,
bone markers, lipids, renal, liver and thyroid function. As the
distribution of fasting insulin levels is usually skewed measures of
insulin sensitivity were log-transformed [23]. As per protocol, any
missing data from premature withdrawal was replaced by at least
one post-baseline measured efficacy parameter that was carried
forward. Efficacy evaluation was based on the intention to treat
population (ITT), where all patients who received at least one dose
of mifepristone and from whom at least one efficacy measurement
is obtained after the study treatment start were analysed. All
Figure 1. Flow chart indicating the different phases of the study to week four as recommended by the TREND statement [14].
Analysis performed at week four as all six patients had insulin resistance and blood pressure measurements suitable for analysis.
doi:10.1371/journal.pone.0060984.g001
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significances were two-sided and values of p,0.05 were regarded
as statistically significant.
Results
Baseline Characteristics
Demographic data for each subject and means (695%CI) are
shown in Table 1. Baseline characteristics were similar to the
target population of interest [24,25].
Hypothalamo-pituitary-adrenal axis analysis
Mifepristone blocked glucocorticoid action as evidenced by
activation of the HPA axis. Baseline mean serum cortisol level was
372.5 nmol/l (95%CI 309.0–435.9 nmol/l), this increased pro-
gressively in each subject, such that at one week levels had
increased significantly (1065 nmol/l 95% CI 636.0–1495.4 nmol/
l; p = 0.03) and further increased by 4 weeks (1551 nmol/l (95%CI
615–2486 nmol/l; p = 0.03). Baseline mean plasma ACTH was
low at 1.9 pmol/l (95%CI 0.7–3.1 pmol/l) whilst plasma ACTH
levels at 4 weeks were 13.6 pmol/l (95%CI 4.4–22.9 pmol/l;
p = 0.03) (Figure 3a). Baseline mean salivary cortisol levels at
0900 h and 2300 h were 4.8 nmol/l (95%CI 3.4–6.2 nmol/l) and
1.3 nmol/l (95%CI 0.2–2.4 nmol/l), respectively. There was a
significant increase in salivary cortisol over 4 weeks at 0900 h
(99.3 nmol/l; p = 0.03) and 2300 h (9.4 nmol/l; p = 0.03)
(Figure 3b).
Figure 2. Study Design showing investigations and intervention performed on six patients from baseline to four weeks. One subject
was withdrawn after end of second week. 1variables measured at baseline and end of study. OGTT: Oral Glucose Tolerance Test - insulin & glucose at
0, 15, 30, 60, 90, 120 min, F: cortisol, ACTH: Adrenocorticotropic Hormone, U & E: urea, electrolytes and creatinine, LFT: Liver Function Tests, FBC: Full
Blood Count, TFT: Thyroid Function Tests.
doi:10.1371/journal.pone.0060984.g002
Table 1. Demographic data – Subject Baseline Characteristics.
Subject 1 2 3 4 5 6 Mean (±95% CI)
Gender M F F F M M
Age (yrs) (range) 72 58 74 56 64 75 67 (58–75)
Mean Weight (kg) 86.0 75.6 70.9 109.0 101.5 110.0 92.2 (74.3–110.0)
Mean BMI (kgm2) 29.1 31.1 24.5 43.7 32.0 39.9 33.4 (26.9–40.5)
Serum Cortisol post ONDST (nmol/l) 67.9 104.0 83.9 88.8 59.9 73.9 79.7 (63.2–96.3)
Serum Cortisol post LDDST (nmol/l) 80.0 54.1 85.0 105.1 80.0 61.0 77.5 (58.2–96.8)
0900 h salivary cortisol (nmol/l) 4.7 6.8 5.2 3.4 5.3 3.4 4.8 (3.4–6.2)
2300 h salivary cortisol (nmol/l) 0.5 0.6 0.9 3.0 2.1 0.5 1.3 (0.2–2.4)
ACTH (pmol/l) 1.9 1.1 2.0 4.1 1.1 1.2 1.9 (0.9–2.9)
Side of adenoma R R L R R R
Size of adenoma (cm) 3.8 2.5 3.6 3.5 2.7 2.0 3.02 (2.3–3.8)
24-hour blood pressure 136/91 143/75 149/86 150/86 138/81 147/77
Fasting glucose (mmol/l) 4.8 6.3 4.7 4.9 5.1 6.5 5.4 (4.6–6.2)
Fasting insulin (pmol/l) 44.4 124.2 34.0 177.1 69.2 86.8 76.4 (39.9–146.4)1
ONDST: Overnight dexamethasone suppression test; LDDST: 48-hour 2 mg low dose dexamethasone suppression test; R = Right, L = Left;
1Geometric mean.
doi:10.1371/journal.pone.0060984.t001
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Changes in insulin resistance
As a group there were significant reductions in IR (lnHOMA-
IR) and improvements in sensitivity (lnMatsuda index) compared
to baseline following mifepristone treatment (Table 2). Five out of
six individuals showed a reduction in insulin AUC (Figure 4). In
subjects 2 and 5 there was a clinically significant reduction in
insulin AUC from above the reference range into the upper half of
the normal reference range. In subjects 1 and 6, insulin AUC fell
by approximately 50% from the upper end of the reference range
to the lower half of the reference range (,26940 pmol/l.min):
patient 1: 51001 pmol/l.min to 25742 pmol/l.min; patient 6:
55972 pmol/l/min to 23668 pmol/l.min. In subject 3 insulin
AUC fell, but this was within the lower half of the reference range
at baseline. Subject 4 was highly insulin resistant and did not show
any improvement in IR.
Changes in other metabolic markers
Subjects 2 and 5 improved their mean 24-hour BP from 143/75
to 135/67 and from 138/81 to 130/81, respectively. As a group
there were no significant changes in resting or ambulatory blood
pressure, serum osteocalcin and urine NTX/creat. There were no
significant differences in the full lipid profile but interestingly there
was a decrease in HDL in Subjects 2 and 5 from 0.93 mmol/l to
0.72 mmol/l and 0.84 mmol/l to 0.6 mmol/l respectively.
Safety analysis
Five subjects completed the study to week four. One (subject 2)
developed clinical symptoms of lassitude and fatigue at end of
week two whilst another developed similar symptoms at the end of
week four (subject 3). Importantly, there was no hypotension,
indicating the relative clinical safety of using mifepristone in this
setting despite the vague symptoms in these individuals. Data
collected for withdrawn subject after week 2 were considered
suitable for analysis as a significant drug effect is achieved by this
time [15]. Serum potassium levels for these subjects were to 3.2
and 3.1 mmol/l, respectively, at the second and fourth week.
There was a significant reversible change in thyroid stimulating
hormone (TSH) (1.45 vs 4.07 mU/l; p = 0.03).
Discussion
We have shown that short-term use of mifepristone can reduce
IR in subjects with adrenal incidentalomas and low-grade
autonomous cortisol secretion. To our knowledge, use of
mifepristone in subjects with adrenal incidentalomas has never
been tested. These data support recent findings in a study in
patients with overt Cushing’s syndrome where an improvement in
insulin AUC and HOMA-IR was shown in the combined diabetes
mellitus/impaired glucose tolerance and hypertension groups [12].
Figure 3. a: Graph showing mean±SEM 0900 h serum cortisol and ACTH levels at baseline and 4 weeks. Activation of the HPA axis, that
is a rise in serum cortisol and ACTH, is already evident one week after starting mifepristone. b: Graph showing mean ±SEM 0900 h and 2300 h
salivary cortisol levels at baseline and 4 weeks. Circadian rhythm of cortisol is maintained evidenced by high levels at 0900 h and low levels at
2300 h, but amplified by the use of mifepristone 200 mg twice per day.
doi:10.1371/journal.pone.0060984.g003
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As a group we showed a significant reduction in IR and five of
our subjects had a decrease in insulin AUC greater than
7237 pmol/l.min, exceeding biological variation. In addition, to
establish whether GR blockade might also be associated with
cardiovascular benefit, we defined our cut-off for insulin AUC
from data published from the Helsinki Policemen Study, which
investigated the relationship between baseline IR and the risk for
cardiovascular disease over 22 years [10]. In that study, on an
OGTT a mean (6SD) insulin AUC of 26940618240 pmol/l.min
was found in those without a future cardiovascular event. We used,
therefore, the mean insulin AUC (62SD) as our 95% reference
range. Using this method we identified two subjects (numbers 2, 5)
who had IR above this level but in whom IR decreased into the
normal range with GR antagonism, consistent with a likely clinical
benefit. Two other subjects (numbers 1, 6) experienced a reduction
of their insulin AUC to the lower half of the reference range, whilst
subject 3 had an insulin AUC value at baseline in the lower half of
the reference range that improved further. Conversely, subject 4
has insulin resistance, which despite GR blockade, was not
reversed. It may be that in some cases insulin resistance is more
Figure 4. Graphs showing the changes in insulin AUC pre (red circle) and post (black square) mifepristone. The upper white area
represents insulin AUC levels associated with increased risk for cardiovascular (CV) events. The grey shaded area represents the insulin AUC upper and
lower 95% reference range (not associated with cardiovascular events). Mean: 26940 pmol/l.min; 2SD: 63420 pmol/l.min. Subjects 2 and 5 show a
clinically significant improvement in their insulin AUC post mifepristone (dotted arrow). Subjects 1 and 6 both show a reduction in insulin AUC from
the upper to the lower 95% reference range (solid arrow). Patient 4 remains at CV risk post mifepristone, indicating no clinical benefit. The insulin
AUC is plotted on the y axis as a logarithmic scale to base 4.
doi:10.1371/journal.pone.0060984.g004
Table 2. Baseline and 4 week insulin sensitivity and glucose tolerance data after the use of mifepristone in 6 patients.
Variable (means ±95% CI) Baseline 4 weeks p value
Fasting glucose (mmol/l) 5.4 (4.6–6.2) 5.6 (5.0–6.1) 0.34
2-hour glucose (mmol/l) 10.2 (8.0–12.5) 11.4 (8.7–14.1) 0.21
AUC glucose (mmol/l.min) 1176 (1013–1339) 1187 (988–1384) 0.60
Geom Fasting insulin (pmol/l)) 76.4 (39.9–146.4) 53.3 (25.8–109.9) 0.03
Geom 2-hour insulin (pmol/l) 628.5 (258.4–1528.3) 420.5 (159.4–1109.5) 0.20
Geom AUC insulin (pmol/l.min) 61973 (30889–124337) 40083 (16020–100289) 0.03
lnHOMA-IR 1.0 (0.2–1.7) 0.6 (20.1–1.4) 0.03
lnHOMA-%b 4.8 (4.2–5.4) 4.3 (3.7–5.0) 0.03
lnMatsuda 1.2 (0.4–1.9) 1.6 (0.7–2.4) 0.03
Repeated measures effect analysed by non-parametric Wilcoxon’s signed rank test.
AUC: Area under the curve HOMA - IR: Homeostatic Model Assessment of Insulin Resistance; HOMA - %b: Homeostatic Model Assessment of Beta Cell function.
doi:10.1371/journal.pone.0060984.t002
Mifepristone in Adrenal Incidentalomas
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e60984
‘fixed’ and less dependent on cortisol. We chose insulin AUC on
OGTT as our primary estimate of IR as this allowed direct
comparison to the seminal Helsinki heart study data examining the
long term effects of IR on cardiovascular risk.
In addition to insulin AUC we used other estimates of insulin
sensitivity. The Matsuda index of whole body insulin sensitivity,
representing a composite of hepatic and peripheral tissues, and which
considers insulin sensitivity in the basal state and after the ingestion of a
glucose load, correlates strongly with estimates of insulin sensitivity
from the ‘gold standard’ euglycemic insulin clamp (r=0.73; p,0.0001)
[21]. Although HOMA, or even stronger, log-transformed HOMA
indices, correlate well with euglycemic clamps, they measure fasting
steady state glucose and insulin concentrations and assume that hepatic
and peripheral insulin sensitivity are equivalent [20,23]. Nonetheless all
insulin sensitivity indices significantly improved. Our data give strong
support to the notion that even mild cortisol excess may be deleterious
on insulin sensitivity/resistance, and that short-term antagonism of GR
may be one means of teasing out which subjects have potentially
reversible IR.
There remains an open question as to whether individuals who have
been identified with adrenal incidentaloma should undergo any
intervention. A number of studies have been carried out in individuals
with cortisol secreting incidentalomas who have been subjected to
adrenalectomy [26,27] and improvements have been noted in weight,
blood pressure, lipid profiles, fibrinogen levels, and glycemic control
[11,28,29,30,31]. There is, however, no consensus on the criteria for
the diagnosis of low-grade cortisol excess in patients with adrenal
incidentalomas [13,27] creating a dilemma on whom should be
referred to surgery. Recently, tests of the HPA axis associated with
known metabolic consequences of hypercortisolemia in these individ-
uals have been suggested [32], but benefit from adrenal surgery has
been demonstrated in subjects without ‘subclinical hypercortisolemia’
[26]. Whilst one interpretation is that this argues against a direct role
for cortisol in their phenotype [27], an alternative interpretation is that
the definition of ‘sub clinical’ is not correct, with some of those
undergoing surgery being labeled as ‘normal’ in fact having clinically
significant excess cortisol. Here, we have used dexamethasone
suppression tests with a serum cortisol cut-off of 50 nmol/l. Diagnosis
was supported by a low mean baseline 0900 h ACTH of 1.9 pmol/l.
Whilst in a general population this strategy runs the risk of including
too many false positives, in an individual with adrenal incidentalomas
there is a considerable a priori likelihood that there is some abnormality of
cortisol secretion, and thus a positive screening raises the post-test
probability of hypercortisolemia to approximately 99% [18,33]. It was
for these reasons that we specifically focused on what would often be
regarded as truly mild cases, to ask the question as to whether we would
see any metabolic changes by antagonizing the GR without a pre-
conceived definition ‘subclinical Cushing’s/hypercortisolemia’; other
than a diagnostic strategy that is in keeping with Endocrine Society
guidelines [18]. Although we did not measure plasma dexamethasone
levels there does not appear to be an advantage to using the 8 mgDST
[34], and thus we feel that it is unlikely that our patients tested false
positive.
As a group no significant changes were detected in the other
metabolic markers investigated. Interestingly the two patients with
clinically significant decreases in insulin AUC (patients 2 and 5)
showed improvements in average 24-hour ambulatory blood
pressure. Meta-analysis of several large prospective studies has
shown that a 5 to 6 mm Hg decrease in diastolic blood pressure is
associated with a 38% reduction in risk for stroke and a 16%
reduction in coronary heart disease events [35], whilst a 10 mmHg
reduction in systolic blood pressure is associated with a reduction
in risk of stroke by one third [36]. Cortisol-induced hypertension is
mediated by several mechanisms including an increased vascular
responsiveness to catecholamines [37], elevated circulating cate-
cholamine levels [38], and potentially, through a mineralocorti-
coid effect, when cortisol occupies the mineralocorticoid receptor
if in excessive amounts consequent to HPA axis activation. The
latter effect could explain why we did not see a significant change
in BP in the group. The decrease in HDL although on first glance
may seem non beneficial, in patients on mifepristone this has
previously been shown to be associated with an increased efflux
capacity of serum HDL on a per particle basis, hence no
proportional impairment in HDL function [39].
As expected with glucocorticoid receptor antagonism the HPA
axis was rapidly activated with serum and salivary cortisol and
plasma ACTH levels rising appropriately. Hence, monitoring of
changes in serum or salivary cortisol can be used to confirm
subject compliance and drug efficacy. Throughout the study as
indicated by the 0900 h/2300 h salivary cortisol ratio the
physiological circadian rhythm of cortisol was maintained but
the amplitude widened with maximal effects of mifepristone
occurring in the morning. Limitations of our pilot study include
the open design, a small sample and two patients were withdrawn
after 2 and 4 weeks of mifepristone treatment, respectively. All
patients received 400 mg per day, in two divided doses of 200 mg.
The two patients who were withdrawn and who developed some
symptoms of adrenal insufficiency were lighter, and hence had the
highest relative dose, followed by highest HPA axis activation.
Importantly, however, there was no hypotension, indicating the
relative clinical safety of using mifepristone in this setting despite
the vague symptoms in these individuals. These data reinforce the
dose-dependent effect of mifepristone, with a dose of around
5 mg/kg/day being most appropriate. The nature of our study
precludes generalization without further studies being performed.
In summary, we have shown that a short period of GR
antagonism for up to four weeks in individuals with mild cortisol
excess resulted in significant improvements in insulin sensitivity,
and potentially clinically significant improvements in two out of
six. These effects can now be examined in randomized controlled
studies to establish whether GR blockade or cortisol-lowering
strategies, are a suitable means for the individualized stratification
of individuals with adrenal incidentaloma to medical or surgical
intervention, or observation.
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